1. Introduction
===============

Ovarian cancer is the most lethal gynecological cancer globally,^\[[@R1],[@R2]\]^ and despite rapid advancements in treatment methods, the prognosis of ovarian cancer patients remains poor, with few effective prognostic biomarkers available at present.^\[[@R3]--[@R5]\]^ Therefore, there is an urgent need for new molecular markers that can be used to predict the prognosis of ovarian cancer patients for the purpose of guiding treatment planning.

As a crucial molecule in posttranscriptional modifications, eukaryotic translation initiation factor 2B subunit 5 (EIF2B5) is important in cancer progression.^\[[@R6]\]^ Early research regarding *EIF2B5* mainly aimed to study the roles of its expression in multiple sclerosis,^\[[@R7],[@R8]\]^ ovarioleukodystrophy,^\[[@R9]\]^ and vanishing white matter (VWM) syndrome.^\[[@R10]--[@R12]\]^ Additionally, recent studies indicated that high *EIF2B5* expressed in few cancerous tissue (lung cancer,^\[[@R13]\]^ breast cancer,^\[[@R14]\]^ and liver cancer^\[[@R15]\]^) and serve as a prognostic biomarker in hepatocellular carcinoma.^\[[@R15]\]^ Nonetheless, the role of *EIF2B5* expression in ovarian cancer remains unclear.

To evaluate the clinical significance of *EIF2B5* expression in the prognosis of ovarian cancer patients, we analyzed the prognostic value of *EIF2B5* mRNA expression in The Cancer Genome Atlas (TCGA) cohort of ovarian cancer patients. First, we analyzed the differential expression of EIF2B5 in ovarian cancer patients and then studied its correlation with overall survival (OS) among the patients.

2. Materials and methods
========================

2.1. Data source
----------------

The clinical data for *EIF2B5* expression in normal ovarian tissues and ovarian cancer tissues were downloaded from the TCGA (<https://cancergenome.nih.gov/>) and GTEx ([www.gtexportal.org/](http://www.gtexportal.org/)) databases in May 2018.

2.2. Data mining
----------------

All data mining was conducted using R (version 3.5.1).^\[[@R16]\]^ The differences in *EIF2B5* expression according to clinical features are shown in boxplots drawn using the ggplot2 package.^\[[@R17]\]^ To determine the high and low EIF2B5 expression groups, and the optimal cutoff value was obtained from ROC curve. Possible clinical correlations between *EIF2B5* expression and the clinical characteristics of ovarian cancer patients were evaluated by the chi square test. The survival curves were drawn using Survival Package.^\[[@R18]\]^ The log-rank test was applied to examine the survival difference. Univariate Cox analysis was performed to select relevant variables, and a multivariate Cox model was used to evaluate the independent prognostic role of *EIF2B5* expression separate from other clinical characteristics.

2.3. GSEA
---------

Gene set enrichment analysis (GSEA) uses predefined gene sets to rank target genes according to the degree of differential expression between the two types of samples, and then to test whether the pre-defined gene sets are at the top or bottom of the sorting table.^\[[@R19]\]^ In the present study, we used GSEA 3.0 software to analyze the data of ovarian cancer patients. We obtained standardized enrichment fractions (NESs) by using permutation analysis 1000 times.

2.4. Ethical approval
---------------------

Ethics committee approval was not necessary because all clinical data used in this study were obtained from a public database and are available for research.

3. Results
==========

3.1. Differential expression of EIF2B5 in ovarian cancer
--------------------------------------------------------

*The data for EIF2B5* expression and clinical features including age, subdivision of cancer, cancer stage, longest dimension, lymphatic invasion, histologic grade, occurrence type, sample type, vital status, and *EIF2B5* expression are presented in Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}A. From the prepared boxplots, *EIF2B5* expression was low in ovarian cancer tissues compared with that observed in normal ovarian tissues. Additionally, low *EIF2B5* expression was observed in deceased patients, suggesting a potential connection between the survival status and *EIF2B5* expression (Fig. [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

###### 

Demographic and clinical characteristics of TCGA ovarian cancer cohort.
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![Differential *EIF2B5* expression in ovarian cancer. The *EIF2B5* expression in all ovarian cancer cases and different groups according to histologic grade, occurrence type, subdivision, lymphatic invasion, patient age, stage, and vital status.](medi-99-e18666-g002){#F1}

###### 

Correlation between *EIF2B5* expression and clinicopathologic characteristics in ovarian cancer.
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3.2. Correlation of EIF2B5 expression and survival
--------------------------------------------------

To explore possible correlations of *EIF2B5* expression with clinical factors, we completed the chi square test and found a specific correlation between vital status and expression of *EIF2B5* (Table [2](#T2){ref-type="table"}). Moreover, patients with shorter OS time had much lower expression of *EIF2B5* (Fig. [2](#F2){ref-type="fig"}, *P* = .034), which is consistent with results of subgroup analysis, especially among the elderly patients (Fig. [2](#F2){ref-type="fig"}, *P* = .022).

![Survival analysis for groups of ovarian cancer cases with differing *EIF2B5* expression in ovarian cancer and subgroup analysis according to early stage, advanced stage, G1 and G2, G3 and G4, lymphatic invasion, non-lymphatic invasion, younger, and older.](medi-99-e18666-g004){#F2}

The univariate Cox model revealed several potential survival-related variables including age, occurrence type, and *EIF2B5* expression. The Multivariate Cox model suggested that low *EIF2B5* expression was an independent risk factor for a poor prognosis in ovarian cancer patients, based on its association with a shorter OS (hazard ratio \[HR\] = 1.82, *P* = .008, Table [3](#T3){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analyses of overall survival duration.
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As shown in Table [4](#T4){ref-type="table"}, GSEA revealed significant differences in the enrichment of the MSigDB Collection (NOM *P* \< .05, false discovery rate \[FDR\] \< 0.25). We chose the most essential signaling pathways based on NES (Table [4](#T4){ref-type="table"}; Fig. [3](#F3){ref-type="fig"}). Figure [3](#F3){ref-type="fig"} shows that mesenchymal transition, angiogenesis, coagulation, and bile acid metabolism were enriched in low *EIF2B5* expression phenotype, respectively.

###### 

Gene set enrichment with low *EIF2B5* expression.
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![Enrichment plots from GSEA.](medi-99-e18666-g007){#F3}

4. Discussion
=============

Although many advances in treatment strategies for ovarian cancer have been explored, the OS of these patients has not been improved. Thus, novel biomarkers that can be used to predict the prognosis of these patients remain urgently needed.^\[[@R20]--[@R26]\]^ According to the results of the present study, low *EIF2B5* expression is an independent risk factor for a poor prognosis among ovarian cancer patients.

Early studies of EIF2B5 mainly focused on its role in VWM diseases, which involve downregulation of EIF2B5.^\[[@R8],[@R10],[@R11]\]^ Recently, several studies began investigating the role of EIF2B5 in various cancers, including lung cancer,^\[[@R13]\]^ breast cancer,^\[[@R14]\]^ and liver cancer.^\[[@R15]\]^ In these studies, EIF2B5 was shown to be overexpressed at both mRNA and protein levels in the cancerous tissues. In contrast, in the present study we observed the opposite phenomenon in which *EIF2B5* expression was lower in ovarian cancer tissues than in normal ovarian tissues. This discrepancy may be due to differences in the cancer types, which might suggest exclusive functions and mechanisms of *EIF2B5* in ovarian cancer. Moreover, *EIF2B5* expression showed a decreasing trend from stage I to stage IV ovarian cancer, suggesting that the function of *EIF2B5* may change throughout different stages of ovarian cancer. To better understand the dynamics of *EIF2B5* expression in ovarian cancer, a subgroup analysis is necessary. Additionally, considering that the low *EIF2B5* expression continued to decline with disease progression, the relationship between *EIF2B5* and survival needs to be further studied.

Previous research also linked EIF2B5 expression with cancer patients' prognosis. A previous study demonstrated that high *EIF2B5* expression is associated with a shorter survival time in colorectal cancer cases.^\[[@R27]\]^ Also, expression of minor alleles of *EIF2B5* was found to improve the prognosis of ovarian cancer patients via the inhibition of angiogenesis and tumor growth.^\[[@R28]\]^ However, the association between *EIF2B5* expression and OS remains unknown in ovarian cancer. In the present study, we found that the overall survival time of ovarian cancer patients with low *EIF2B5* expression was short, while subgroup analysis revealed the same phenomenon with differences in the stage and histologic grade of ovarian cancer. Interestingly, we found that the survival difference was especially significant in older patients. However, this study doesn't contain the variables like race and cancer type, because the races information of TCGA is absent, and only epithelial type exists. Future study needs to explore these variables in other population. Moreover, mesenchymal transition, angiogenesis, coagulation, and bile acid metabolism may be signaling pathways of *EIF2B5* in ovarian cancer.

To the best of our knowledge, this is the first study analyzing the prognostic value of the *EIF2B5* expression in ovarian cancer. Together with other studies of *EIF2B5*, our study provides insight into the role of *EIF2B5* expression in various cancer types. However, as we did not explore the underlying mechanism of the function of EIF2B in ovarian cancer, future in vitro and in vivo experiments are needed to explore the mechanism in depth.

5. Conclusion
=============

In the present study, we investigate the predictive value of *EIF2B5* expression for ovarian cancer patients' prognosis. We found that low *EIF2B5* expression was an independent risk factor for a shorter survival time among ovarian cancer patients. Our future research will include in vitro and in vivo experiments to explore the underlying mechanism of this relationship in depth.
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